# Author Listing of Relationships With Industry and Other Entities (Comprehensive) — ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Name** | **Employment** | **Consultant** | **Speaker** | **Ownership/ Partnership/ Principal** | **Registries** | **Research** | **Salary** | **Institutional, Organizational, or Other Financial Benefit** | **Expert Witness** |
| Deepak L. Bhatt, *Chair* | Brigham and Women’s Hospital, Harvard Medical School | * Elsevier Practice Update Cardiology
* Population Health Research Institute
* DCRI: Novartis †
* DCRI: Bristol-Meyers Squibb/Pfizer
* DCRI: Eli Lilly
 | None | * None
 | Chair, AHA GWTG Steering Committee\*REACH Registry co-Chair | * Roche†
* FlowCo\*
* Amarin†
* Medtronic†
* Takeda\*
* PLx Pharma\*
* Astra Zeneca†
* The Medicines Co. †
* Sanofi Aventis†
* Ethicon†
* Eisai †
* Bristol Myers Squibb†
 | None | * Advisory Board: Elsevier Practice Update Cardiology
* Associate Editor-Clinical Cardiology\*
* Belvoir Publications †
* Regado Biosciences-Advisory Board \*
* Journal of Invasive Cardiology †
* Medscape Cardiology-Advisory Board\*
* WebMD Steering Committee†
* Slack Publications/Cardiovascular Research Foundation: Editor†
* Harvard Clinical Research Institute: Boehringer Ingelheim
* Harvard Clinical Research Institute: St. Jude
* Mayo Clinic: DSMB
* DCRI: DSMB‡
* Society of Chest Pain Centers
* Boston VA Research Institute: Novartis
 | None |
| Joseph P. Drozda, Jr., *Co-Chair* | Mercy Health—Director, Outcomes Research | None | None | None | * Member, NCDR Management Board
 | None |  | * Boston Scientific Rhythm Management†
* PCPI\*
 | None |
| David M. Shahian, *Co-Chair* | Massachusetts General Hospital—Director of Research, Center for Quality and Safety | None  | None | None | * Chair, STS Database Committee
* National Quality Registry Network
 | * STS\*
 |  | * ACCF/AHA Task Force on Performance Measures\*
* STS\*
 | None |
| Paul Chan | Mid America Heart Institute—Assistant Professor of Cardiology | None  | None | None | * Member, PINNACLE Registry
* Member, NCDR Science and Quality Oversight Committee
 | * AHA†
* NHLBI†
 | Mid-America Heart Institute† | * ACC†
* AHA†
 | None |
| Gregg C. Fonarow | Ahmanson-UCLA Cardiomyopathy Center—Director, Division of Cardiology | * Amgen
* Boston Scientific
* Gambro
* Johnson & Johnson
* Medtronic
* Novartis†
* Takeda
 | None | None | * Chair, ACTION-GWTG Steering Committee
 | * NHLBI†
* NIH/NIAID†
* Medtronic\*
* Novartis
* PRT\*
 |  | * ACCF/AHA Task Force on Data Standards\*
* ACCF/AHA Task Force on Performance Measures\*
* ACTION Registry GWTG Steering Committee Chair\*
* AHA Manuscript Oversight Committee\*
 | None |
| Paul A. Heidenreich | Stanford VA Palo Alto Health Care System—Professor of Medicine | None | None | None | * Chair, ICD Registry Research and Publications Committee
 | None |  | * ACCF/AHA Task Force on Performance Measures\*
* Core-Valve Research Trial\*
 | None |
| Jeffrey P. Jacobs | Cardiac Surgical Associates | None | None | None | None | * COAST DSMB
* NIH
 |  | None | None |
| Frederick A. Masoudi | University of Colorado at Denver—Associate Professor of Medicine, Division of Cardiology | None | None | None | * NCDR Chief Science Officer†
 | * AHRQ†
* NHLBI
* Oklahoma Foundation for Medical Quality†
 | * ACCF†
 | * AHA
* Massachusetts Medical Society
 | * 2012, Plantiff, acute coronary syndrome
 |
| Eric D. Peterson | Duke Clinical Research Institute—Professor of Medicine | * Janssen
 | None | None | * Member, NCDR Science and Quality Oversight Committee (ex officio)\*
* STS/ACC TVT Registry\*
 | * Eli Lilly†
* Janssen†
 | * DCRI‡
 | * ACCF/AHA Task Force on Performance Measures\*
 | None |
| Karl Welke |  | None | None | None | None | None | None | None | None |

\*No financial relationship.

†Significant (greater than $10,000) relationship.

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a *relevant* relationship IF: a) the *relationship or interest* relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the *document*; or b) the *company/entity* (with whom the relationship exists) makes a drug, drug class, or device addressed in the *document*, or makes a competing drug or device addressed in the *document*; or c) the *person or a member of the person’s household* has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the *document*.

\*No financial relationship.

†Significant (greater than $10,000) relationship.

‡DCRI has numerous grants and contracts sponsored by industry. These include the following: Aastrom Biosciences†; Abbott†; Abiomed†; Acom Cardiovascular†; Adolor Corp.†; Advanced Cardiovascular Systems†; Advanced Stent Technologies†; Adynnx; Aijnomoto†; Allergan†; Amgen†; Alnylam Pharma†; Alpharma†; Amylin Pharmaceuticals†; Anadys†; Anesiva†; Angel Medical Systems†; ANGES MG†; Angiomedtrix†; APT Nidus Center†; ASCA Biopharma†; Astellas Pharma†; Asklepios†; AstraZeneca†; Atritech†; Attention Therapeutics†; Aventis†; Baxter†; Bayer†; Berlex†; BG Medicine†; Biogen†; Biolex Therapeutics†; Biomarker Factory†; Biosite†; Boehringer Ingelheim Biogen†; Boston Scientific†; Bristol-Myers Squibb†; BMS Pfizer†; Carbomed†; CardioDx†; CardioKinetix†; Cardiovascular Systems†; Cardiovax†; Celsion Corp.†; Centocor†; Cerexa†; Chase Medical†; Conatus Pharmaceuticals†; Conor Medsystems†; Cortex†; Corgentech†; CSL Behring†; CV Therapeutics†; Daiichi Pharmaceuticals†; Daiichi-Sankyo†; Daiichi-Sankyo Lilly†; Datascope; Dendreon†; Dainippon†; Dr. Reddy’s Laboratories; Eclipse Surgical Technologies†; Edwards Lifesciences†; Eisai†; Endicor†; EnteroMedics†; Enzon Pharmaceuticals†; Eli Lilly†; Ethicon†; Ev3†; Evalve†; F2G†; Flow Cardia†; Fox Hollow Pharmaceuticals†; Fujisawa†; Genetech†; General Electric†; General Electric Co.†; General Electric Healthcare†; General Electric Medical Systems†; Genzyme Corp.†; Genome Canada†; Gilead Sciences†; GlaxoSmithKline†; Guidant Corp.†; Heartscape Technologies†; Hoffman-LaRoche†; Hospira†; Idera Pharmaceuticals†; Ikaria†; Imcor Pharmaceuticals†; Immunex†; INFORMD†; Inimex†; Inspire Pharmaceuticals†; Ischemix†; Janssen†; Johnson and Johnson†; Jomed†; Juventus Therapeutics†; KAI Pharmaceuticals†; King Pharmaceuticals†; Kyowa Pharma†; Luitpold†; Mardil†; MedImmune†; Medscape†; Medtronic Diabetes†; Medtronic†; Medtronic Vascular†; Merck Group†; MicroMed Technology†; Millennium Pharmaceuticals†; Mitsubishi Tanabe†; Momenta†; Nabriva†; Neuron Pharmaceuticals†; NitroMed; NovaCardia Inc†; Novartis AG Group†; Novartis Pharmaceuticals†; Oncura†; Orexigen†; Ortho-McNeil-Janssen†; OSI Eyetech†; OSI Pharmaceuticals†; Pfizer†; Pharmacyclics†; Pharmasset†; Pharmos†; Phyxius Pharmaceuticals; Pharsight†; Pluristen Therapeutics†; Portola Pharmaceuticals†; Proventys†; Radiant†; Regado Biosciences†; Rengeneron Pharmaceuticals†; Roche Molecular Systems†; Roche Group†; Roche Diagnostic†; Salix Pharmaceuticals†; Sanofi-Pasteur, Inc; Sanofi-aventis†; Santaris Pharmaceuticals†; Schering-Plough†; Scios†; Siemens†; Southwest Oncology Group†; Spectranetics†; Summit†; Sunovion Pharmaceuticals†; TAP Pharmaceutical Products†; Tengion†; The Medicines Company†; Theravance†; TherOx†; Tethys Bioscience†; Theregen†; Three Rivers Pharmaceuticals†; The EMMES Corporation†; UCB†; Valentis†; Valleylab†; Vertex†; Viacor†; and Wyeth†.

ACC indicates American College of Cardiology; AHA, American Heart Association; DCRI, Duke Clinical Research Institute; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.